Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose…
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
- Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending…
Precision BioSciences to Report Third Quarter Results on November 4, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo…
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 28, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo…
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
- Stimulating gene editing by homology-directed repair (HDR) has the potential advantage of being able to achieve any type of edit, including gene insertion - ARCUS approach potentially offers…
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
- Clinical Trial Application accepted in Moldova with additional regulatory applications pending approval - PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move…
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo…
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 16, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 3, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
- PBGENE-HBV is the only drug modality designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV - Clinical trial applications submitted for the first gene…
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
- Murray Abramson , MD, MPH appointed as Senior Vice President, Head of Clinical Development- - John Fry appointed as Strategic Clinical Advisor, Hepatitis - - Alan List , MD, Chief Medical Officer…
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 4, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
-- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares-- --The addition of this cash further reinforces Precision’s expected cash runway into the second half of…
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
- Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. --(BUSINESS WIRE)--Aug. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing…